Chemotherapy for malignant mesothelioma; CAMEO.
Twelve patients with a tissue diagnosis of malignant mesothelioma were treated with combination chemotherapy (CAMEO) every 4-5 weeks, with or without hemithoracic radiation. Mean survival from the time of tissue diagnosis an start of protocol treatment was 15.7 and 12.6 months, respectively. Median survival from the time of tissue diagnosis and start of protocol treatment was 11 and 6.5 months, respectively. Two patients were long-term survivors (32 and 45 months), one of whom is alive without evidence of recurrent disease. Toxicity from this regimen was moderate.
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D004359:Drug Therapy, Combination; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D008297:Male; D008654:Mesothelioma / Q000188:drug therapy* / Q000532:radiotherapy; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects; D008875:Middle Aged; D010997:Pleural Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D011379:Prognosis; D011879:Radiotherapy Dosage; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D008727:Methotrexate